Bovine thrombin: History, use, and risk in the surgical patient

Vascular

Volumn 16, Issue SUPPL. 1, 2008, Pages

  Diesen, Diana L ^a   Lawson, Jeffrey H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bovine thrombin; Coagulation; Immunology

Indexed keywords

THROMBIN;

BLEEDING; DRUG USE; HEMOSTASIS; HISTORY OF MEDICINE; HUMAN; IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SURGICAL PATIENT; THROMBOSIS;

EID: 44349168362     PISSN: 17085381     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Schmidt A. Uber den Faserstoff und die Ursache seiner Gerinnung. Arch Anat Physiol 1861;545-675.
2. Schmidt A. Neue Untersuchungen uber die Faserstoffgerinnung. Pflugers Arch Ges Physiol 1872;6:413.
3. Schmidt A. Zur Blutlehre. Leipzig (Austria): Vogel; 1892.
4. Lundblad RL, Fenton JW, Mann KG. Chemistry and biology of thrombin. Ann Arbor (MI): Ann Arbor Science; 1977.
5. Dahlbäck B. Blood coagulation. Lancet 2000;355:1627-32.
6. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999;82:165-74.
7. Bar-Shavit R, Hruska KA, Kahn AJ, Wilner GD. Thrombin chemotactic stimulation of HL-60 cells: studies on thrombin responsiveness as a function of differentiation. J Cell Physiol 1987;131:255-61.
8. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258-64.
9. Coughlin SR. Sol Sherry lecture in thrombosis: how thrombin 'talks' to cells: molecular mechanisms and roles in vivo. Arterioscler Thromb Vasc Biol 1998;18:514-8.
10. Stenberg PE, McEver RP, Shuman MA, et al. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985;101:880-6.
11. Henn V, Slupsky JR, Gräfe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-4.
12. Subramaniam M, Frenette PS, Saffaripour S, et al. Defects in hemostasis in P-selectin-deficient mice. Blood 1996;87:1238-42.
13. Cirino G, Cicala C, Bucci MR, et al. Thrombin functions as an inflammatory mediator through activation of its receptor. J Exp Med 1996;183:821-7.
14. Crago AM, Wu HF, Hoffman M, Church FC. Monocyte chemoattractant activity of Ser195 - >Ala active site mutant recombinant alpha-thrombin. Exp Cell Res 1995;219:650-6.
15. Hoffman M, Church FC. Response of blood leukocytes to thrombin receptor peptides. J Leukoc Biol 1993;54:145-51.
16. Hoffman M, Cooper ST. Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 beta by two distinct mechanisms. Blood Cells Mol Dis 1995;21:156-67.
17. Herbert JM, Dupuy E, Laplace MC, et al. Thrombin induces endothelial cell growth via both a proteolytic and a non-proteolytic pathway. Biochem J 1994;303 (Pt 1):227-31.
18. Patterson C, Stouffer GA, Madamanchi N, Runge MS. New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. Circ Res 2001;88:987-97.
19. Gilchrist A, Vanhauwe JF, Li A, et al. G alpha minigenes expressing C-terminal peptides serve as specific inhibitors of thrombin-mediated endothelial activation. J Biol Chem 2001;276:25672-9.
20. Gamba G, Fornasari PM, Grignani G, et al. Haemostasis during transvesical prostatic adenomectomy. A controlled trial on the effect of drugs with antifibrinolytic and thrombin-like activities. Blut 1979;39:89-98.
21. Rengachary SS, Manguoglu AB. Control of bone bleeding during Cloward procedure. Technical note. J Neurosurg 1980;52:138-9.
22. Verstraete M. Hemostatic drugs. In: Bloom AL, editor. Haemostasis and thrombosis. Edinburgh: Churchill Livingstone; 1987. p. 607-17.
23. Reeder SB, Widlus DM, Lazinger M. Low-dose thrombin injection to treat iatrogenic femoral artery pseudoaneurysms. AJR Am J Roentgenol 2001;177:595-8.
24. Ferguson JD, Whatling PJ, Martin V, et al. Ultrasound guided percutaneous thrombin injection of iatrogenic femoral artery pseudoaneurysms after coronary angiography and intervention. Heart 2001;85:E5.
25. Vaziri ND. Topical thrombin and control of bleeding from the fistula puncture sites in dialyzed patients. Nephron 1979;24:254-6.
26. Seegers WH, Warner ED, Brinkhous KM, Smith HP. The use of purified thrombin as an hemostatic agent. Science 1939;89:86.
27. Warner ED, Brinkhous KM, Seegers WH, Smith HP. Further experience with the use of thrombin as a hemostatic agent. Proc Soc Exp Biol 1939;41:655-7.
28. Tidrick RT, Seeger WH, Warner ED. Clinical experience with thrombin as an hemostatic agent. Surgery 1943;14:191-6.
29. Rapaport SI, Zivelin A, Minow RA, et al. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol 1992;97:84-91.
30. Cmolik BL, Spero JA, Magovern GJ, Clark RE. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency. J Thorac Cardiovasc Surg 1993;105:222-227; discussion 227-8.
31. Israels SJ, Leaker MT. Acquired inhibitors to factors V and X after exposure to topical thrombin: interference with monitoring of low molecular weight heparin and warfarin. J Pediatr 1997;131:480-3.
32. Sands JJ, Nudo SA, Ashford RG, et al. Antibodies to topical bovine thrombin correlate with access thrombosis. Am J Kidney Dis 2000;35:796-801.
33. Kajitani M, Ozdemir A, Aguinaga M, et al. Severe hemorrhagic complication due to acquired factor V inhibitor after single exposure to bovine thrombin product. J Card Surg 2000;15:378-82.
34. Ortel TL, Mercer MC, Thames EH, et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001;233:88-96.
35. Schoenecker JG, Hauck RK, Mercer MC, et al. Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose. J Clin Immunol 2000;20:434-44.
36. Su Z, Izumi T, Thames EH, et al. Antiphospholipid antibodies after surgical exposure to topical bovine thrombin. J Lab Clin Med 2002;139:349-56.
37. Cruickshank MK, Black J, Wall W. Development of a factor V and thrombin inhibitor following partial hepatic resection and the use of topical thrombin concentrate. Clin Lab Haematol 1994;16:187-90.
38. Izumi T, Kim SW, Greist A, et al. Fine mapping of inhibitory anti-factor V antibodies using factor V C2 domain mutants. Identification of two antigenic epitopes involved in phospholipid binding. Thromb Haemost 2001;85:1048-54.
39. Ortel TL, Moore KD, Quinn-Allen MA, et al. Inhibitory anti-factor V antibodies bind to the factor V C2 domain and are associated with hemorrhagic manifestations. Blood 1998;91:4188-96.
40. Stricker RB, Lane PK, Leffert JD, et al. Development of antithrombin antibodies following surgery in patients with prosthetic cardiac valves. Blood 1988;72:1375-80.
41. Flaherty MJ, Henderson R, Wener MH. Iatrogenic immunization with bovine thrombin: a mechanism for prolonged thrombin times after surgery. Ann Intern Med 1989;111:631-4.
42. Lawson JH, Pennell BJ, Olson JD, Mann KG. Isolation and characterization of an acquired antithrombin antibody. Blood 1990;76:2249-57.
43. Chapman WC, Singla N, Genyk Y, et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg 2007;205:256-65.
44. Neschis DG, Heyman MR, Cheanvechai V, et al. Coagulopathy as a result of factor V inhibitor after exposure to bovine topical thrombin. J Vasc Surg 2002;35:400-2.
45. Heffernan JK, Ponce RA, Zuckerman LA, et al. Preclinical safety of recombinant human thrombin. Regul Toxicol Pharmacol 2007;47:48-58.
46. Crow SS, Sullivan VV, Aysola AE, et al. Postoperative coagulopathy in a pediatric patient after exposure to bovine topical thrombin. Ann Thorac Surg 2007;83:1547-9.
47. Spero JA. Bovine thrombin-induced inhibitor of factor V and bleeding risk in postoperative neurosurgical patients. Report of three cases. J Neurosurg 1993;78:817-20.
48. Berruyer M, Amiral J, Ffrench P, et al. Immunization by bovine thrombin used with fibrin glue during cardiovascular operations. Development of thrombin and factor V inhibitors. J Thorac Cardiovasc Surg 1993;105:892-7.
49. Streiff MB, Ness PM. Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion 2002;42:18-26.
50. Tarantino MD, Ross MP, Daniels TM, Nichols WL. Modulation of an acquired coagulation factor V inhibitor with intravenous immune globulin. J Pediatr Hematol Oncol 1997;19:226-31.
51. Israels SJ, Israels ED. Development of antibodies to bovine and human factor V in two children after exposure to topical bovine thrombin. Am J Pediatr Hematol Oncol 1994;16:249-54.
52. Bänninger H, Hardegger T, Tobler A, et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Haematol 1993;85:528-32.
53. Zumberg MS, Waples JM, Kao KJ, Lottenberg R. Management of a patient with a mechanical aortic valve and antibodies to both thrombin and factor V after repeat exposure to fibrin sealant. Am J Hematol 2000;64:59-63.
54. Poynton AR, Nelson MC, McCance SE, et al. Bovine thrombin induces an acquired coagulopathy in sensitized patients undergoing revision spinal surgery: a report of two cases. Spine 2003;28:E221-3.
55. Zehnder JL, Leung LL. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990;76:2011-6.
56. Loeliger A, Hers JF. Chronic antithrombinaemia (antithrombin V) with haemorrhagic diathesis in a case of rheumatoid arthritis with hypergammaglobulinaemia). Thromb Diath Haemorrh 1957;1:499-528.
57. Hawiger J, Hanicki Z, Struzik T. On the immunologic nature of antithrombin in the course of lupus erythematosus disseminatus. Acta Med Pol 1964;5:53-60.
58. Galanakis DK, Newman J, Summers D. Circulating thrombin time anticoagulant in a procainamide-induced syndrome. JAMA 1978;239:1873-4.
59. Scully MF, Ellis V, Kakkar VV, et al. An acquired coagulation inhibitor to factor II. Br J Haematol 1982;50:655-64.
60. Barthels M, Heimburger N. Acquired thrombin inhibitor in a patient with liver cirrhosis. Haemostasis 1985;15:395-401.
61. Gabriel DA, Carr ME, Cook L, Roberts HR. Spontaneous antithrombin in a patient with benign paraprotein. Am J Hematol 1987;25:85-93.
62. Seegers WH. Thrombin as a hemostatic agent. In Prothrombin. Boston: Harvard University Press; 1962. p. 581-91.
63. Machovich R. Clinical use of thrombin. In: Machovich R, editor. Thrombin. Vol 2. Boca Raton (FL): CRC Press; 1984. p. 105-6.
64. Sands JJ, Nudo SA, Moore KD, Ortel TL. Antibodies to prothrombin, factor V, and beta2-glycoprotein I and vascular access thrombosis. ASAIO J 2001;47:507-10.
65. Lawson JH, Lynn KA, Vanmatre RM, et al. Antihuman factor V antibodies after use of relatively pure bovine thrombin. Ann Thorac Surg 2005;79:1037-8.
66. Sarfati MR, Dilorenzo DJ, Kraiss LW, Galt SW. Severe coagulopathy following intraoperative use of topical thrombin. Ann Vasc Surg 2004;18:349-51.
67. Ortel TL, Neal MC, Thames EH, et al. Inhibitor development after surgical exposure to bovine thrombin: antibody spectrum and clinical outcomes. Blood Cells Mol Dis 1997;90:469a.
68. Erlanger BF. Auto-anti-idiotypy, autoimmunity and some thoughts on the structure of internal images. Int Rev Immunol 1989;5:131-7.
69. Hall R. Molecular mimicry. Adv Parasitol 1994;34:81-132.
70. Behar SM, Porcelli SA. Mechanisms of autoimmune disease induction. The role of the immune response to microbial pathogens. Arthritis Rheum 1995;38:458-76.
71. Moran AP, Prendergast MM, Appelmelk BJ. Molecular mimicry of host structures by bacterial lipopolysaccharides and its contribution to disease. FEMS Immunol Med Microbiol 1996;16:105-15.
72. Atkinson MA. Molecular mimicry and the pathogenesis of insulin-dependent diabetes mellitus: still just an attractive hypothesis. Ann Med 1997;29:393-9.
73. Karlsen AE, Dyrberg T. Molecular mimicry between non-self, modified self and self in autoimmunity. Semin Immunol 1998;10:25-34.
74. Albert LJ, Inman RD. Molecular mimicry and autoimmunity. N Engl J Med 1999;341:2068-74.
75. Mamula MJ. Epitope spreading: the role of self peptides and autoantigen processing by B lymphocytes. Immunol Rev 1998;164:231-9.
76. Schoenecker JG, Johnson RK, Lesher AP, et al. Exposure of mice to topical bovine thrombin induces systemic autoimmunity. Am J Pathol 2001;159:1957-69.
77. Mercer M, Mayward T, Ortel T and Lawson J. Increased cost associated with surgical exposure to bovine thrombin. Int Society Throm Hemost 2001; abstract, P2632.